Custom synthesis (CDMO): Emissions
Why pharma giants now ask their suppliers for green power
What this tab covers The greenhouse-gas footprint per tonne, split by lifecycle phase (feedstock, production, movement, use, end of life), the global total, other environmental impacts, levers and low-carbon routes, India's position, and where the investment opportunity lies. Emission intensity 48.5 t CO2e per $ million revenue (pharma sector average, 2015) range varies widely by company and modality · sector-wide intensity for 15 large pharma companies, scopes 1 and 2 plus reported scope 3 where available; CDMO-specific average not published Global emissions per year 8.40 Mt CO2e per year 2025 · 48.55 t/$m x $173.7 billion CDMO revenue (derived, indicative; mixes years and scopes)Per t CO2e per $ million revenue (service business); per kg API for products. Intensity: Belkhir and Elmeligi, J. Cleaner Production 214 (2019) (indicative for CDMOs). Global total: derived (indicative).
Share of footprint by lifecycle phase
Feedstock 50% Production / process 45% Movement 5%Footprint by lifecycle phase
| Phase | Intensity | Share | Main sources of emissions | Notes | Source |
|---|---|---|---|---|---|
| Feedstock | purchased solvents, reagents, single-use plastics | 50% | scope 3 purchased goods | indicative | indicative |
| Production / process | steam, power, HVAC for cleanrooms, incineration | 45% | coal-heavy power in India and China | indicative | indicative |
| Movement | air freight of samples and APIs | 5% | air freight | indicative | indicative |
| Use | not applicable | – | attributed to drug products | ||
| End of life | solvent and hazardous waste incineration | – | waste treatment | often counted in process |
Other environmental impacts
Hazardous solvent waste, potent compound releases, single-use plastics in biologics.
Levers to cut emissions
- Renewable power purchase agreements (big pharma customers increasingly require supplier targets)
- Solvent recovery and green chemistry at route design
- Electrified steam and heat pumps
- Supplier engagement programmes such as the Energize initiative for pharma suppliers (indicative)
India
Indian CDMOs report emissions in BRSR filings; customers' scope 3 targets are pushing them toward renewable power (no aggregate figure found).
Emission figures are indicative global averages from the life-cycle studies named; actual footprints vary widely by site, energy mix and method.Low-carbon routes
| Route | Intensity | Cost premium | Status | Source |
|---|---|---|---|---|
| Green chemistry route design at development stage | PMI reductions of half or more in award cases (indicative) | often cost-saving | standard practice at leading CDMOs | ACS GCI Pharmaceutical Roundtable (indicative) |